Targeting Resistant prostate cancer with ATR and PARP inhibition (TRAP trial)

IRB/UVA Tracking #
Principal Investigator
Michael Devitt
Julio Torres III
Contact Phone
Official Trial Title
A Multi-Center Phase II Study Testing the Activity of Olaparib and AZD6738 (ATR Inhibitor) in Metastatic Castration-Resistant Prostate Cancer.
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for adults ages 18 and over who have metastatic castration resistant prostate cancer (MCRPC). The purpose of this study is to see if combining AZD6783, an investigational drug, with Olaparib, a drug used to treat prostate cancer will slow down the rate of growth in prostate cancer.

Participation may last up to 3 years. This includes screening, treatment, and end of treatment visits. We will also follow your post-study progress for up to 5 years. Study specific tests will be provided at no cost to you.

Additional information can be found here: